The Safety, Tolerability, and Pharmacokinetics of TPN171H Tablets in Patients With Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2020-10-14
Target enrollment:
Participant gender:
Summary
Exploring the safety, tolerability, and pharmacokinetic (PK) characteristics of oral TPN171H
tablets in patients with Pulmonary Arterial Hypertension under continuous multiple
administration conditions, providing a basis for determining the administration plan and
recommended dosage in phase II clinical study.
Phase:
Phase 1
Details
Lead Sponsor:
Vigonvita Life Sciences
Collaborator:
Shanghai Institute of Materia Medica, Chinese Academy of Sciences